GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Greenyn Biotechnology Co Ltd (ROCO:6846) » Definitions » Price-to-Owner-Earnings

Greenyn Biotechnology Co (ROCO:6846) Price-to-Owner-Earnings : (As of Jun. 05, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Greenyn Biotechnology Co Price-to-Owner-Earnings?

As of today (2024-06-05), Greenyn Biotechnology Co's share price is NT$75.80. Greenyn Biotechnology Co does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Greenyn Biotechnology Co's Price-to-Owner-Earnings or its related term are showing as below:


ROCO:6846's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.78
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-05), Greenyn Biotechnology Co's share price is NT$75.80. Greenyn Biotechnology Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was NT$5.30. Therefore, Greenyn Biotechnology Co's PE Ratio for today is 14.30.

As of today (2024-06-05), Greenyn Biotechnology Co's share price is NT$75.80. Greenyn Biotechnology Co's EPS without NRI for the trailing twelve months (TTM) ended in was NT$5.30. Therefore, Greenyn Biotechnology Co's PE Ratio without NRI for today is 14.32.

During the past 5 years, Greenyn Biotechnology Co's highest PE Ratio without NRI was 22.03. The lowest was 9.21. And the median was 15.13.


Greenyn Biotechnology Co Price-to-Owner-Earnings Historical Data

The historical data trend for Greenyn Biotechnology Co's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Greenyn Biotechnology Co Price-to-Owner-Earnings Chart

Greenyn Biotechnology Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
- - - - -

Greenyn Biotechnology Co Quarterly Data
Dec19 Jun20 Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Greenyn Biotechnology Co's Price-to-Owner-Earnings

For the Biotechnology subindustry, Greenyn Biotechnology Co's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Greenyn Biotechnology Co's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Greenyn Biotechnology Co's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Greenyn Biotechnology Co's Price-to-Owner-Earnings falls into.



Greenyn Biotechnology Co Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Greenyn Biotechnology Co's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=75.80/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Greenyn Biotechnology Co  (ROCO:6846) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Greenyn Biotechnology Co Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Greenyn Biotechnology Co's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Greenyn Biotechnology Co (ROCO:6846) Business Description

Traded in Other Exchanges
N/A
Address
5th Floor, No 43 Keya Road, Daya District, Taichung, TWN
Greenyn Biotechnology Co Ltd has developed Insumate patented sequenced peptide, Antromax Antrodia cinnamomea mycelia, and Zymologist fermented liquid.

Greenyn Biotechnology Co (ROCO:6846) Headlines

No Headlines